CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML relapse thereby negatively impacting disease outcome. Over the last years myeloid derived sup...

詳細記述

保存先:
書誌詳細
出版年:J Immunother Cancer
主要な著者: Jitschin, Regina, Saul, Domenica, Braun, Martina, Tohumeken, Sehmus, Völkl, Simon, Kischel, Roman, Lutteropp, Michael, Dos Santos, Cedric, Mackensen, Andreas, Mougiakakos, Dimitrios
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2018
主題:
Short Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217777/
https://ncbi.nlm.nih.gov/pubmed/30396365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0432-9
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料